BTIG Upgrades Edwards Lifesciences (EW) to Buy

BTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3 data.

"This is medically changing data of rare magnitude and far better than expected. We’ve felt THVs would be superior in sicker pts but weren’t sure in less sick patients. While equal would have converted the entire market, superiority should cause this much faster," said analsyt Sean Lavin.

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $89.92 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades GEA Group AG (G1A:GR) (GEAGY) to Equalweight
• Jefferies Starts Trastor Real Estate Investment Co (TRASTOR:GA) at Buy
• HSBC Downgrades Hermes International (RMS:FP) (HESAY) to Hold